BPC-157 vs TB-500

At a glance

Evidence grade

The short answer

BPC-157 and TB-500 are unrelated molecules with unrelated origins that arrived at the same place in the market. Both are sold on a repair-and-recovery story. Both rest on animal work. Neither has a controlled human trial base.

The honest comparison between them is not which one works better, because no study has established that either works in people for the uses being marketed. It is what kind of evidence each one has, where that evidence came from, and what it can and cannot support.

Both also sit in an unresolved regulatory position, and neither can lawfully be compounded for a patient as things stand. That is not a footnote to the comparison. It is part of what a reader is choosing between.

Two different biological stories

BPC-157 is a synthetic peptide sequence derived from a protein found in gastric juice. The original scientific interest was in protection and repair of the digestive tract lining, which is where the sequence was identified.

TB-500 is a synthetic version of a fragment of thymosin beta-4, a protein studied for its part in how cells move during tissue repair. The interest there is about cell migration, not about the gut.

They are not variants of each other and they do not share a mechanism. That matters, because their joint presence in the same vials creates an impression of a family that does not exist biologically.

What the published work actually is

The literature behind BPC-157 is animal research, largely rodent injury models. Results in those models have been reported across a range of tissues, and that breadth is a large part of why the compound attracted attention.

What exists for TB-500 is cell and animal studies on wound and tissue repair, sitting alongside a long tail of athlete and forum reporting that is not evidence in any usable sense.

Preclinical results are where hypotheses come from, not where they are confirmed. The distance between an effect in a rodent injury model and a benefit a person can detect is enormous. The history of medicine is largely a record of compounds that cleared the first bar and failed the second. Most public writing about both compounds presents preclinical results as though they were clinical ones.

Why they are sold in the same vial

Vendors routinely list them together, and combined vials pairing the two appear across the market. The commercial logic is that both are marketed for tissue repair, so bundling them widens the claim without widening the evidence.

There is no controlled human trial of the combination, just as there is none of either compound alone for these uses. Bundling two untested compounds does not produce a tested product.

It does produce a persuasive one. Two names, two mechanisms, one recovery promise — the pitch sounds more thorough than a single compound would. That is a marketing effect, not a pharmacological one.

What "no controlled human evidence" means here, and what it does not

Both compounds are graded no controlled human evidence. The tier is not "no research". It describes what has been measured in people, which for these two is close to nothing relevant to the uses on offer.

It is not a claim that either compound is dangerous. Being under-studied and being proven harmful are different findings, and this grade is the first one.

It is also not a claim that the animal work is worthless. That work is real, and it is why anyone is interested. The problem is the step that was skipped, not the step that was taken.

Where the regulatory question sits

No FDA-approved product stands behind either compound in any indication. Neither may lawfully be compounded for a patient as things stand, and anything being sold for human use today is sold ahead of any rule that would permit it rather than under one.

Whether that position changes is undecided, and no outcome, timeline or likelihood is stated here. Each compound has a dated status record on this site, and that record is where the current position is stated.

One consequence is worth being plain about. Most of what circulates under both names is sold in vials labeled for research use only. That material sits outside the prescription drug supply chain. It carries no assurance of identity, purity, sterility or content. That is a different question from the regulatory one, and it does not resolve with it.

How the grades were set

Both sit in the lowest of this site’s three tiers, and they sit there for the same reason. Each has a preclinical file and no published controlled human trial base for the outcomes it is sold on.

Neither compound is being graded down for its regulatory position. The grade measures evidence, and evidence is what is missing here. The regulatory position is recorded separately because it answers a different question.

A grade moves when the evidence moves. For either compound that would mean controlled human trials, in people with the problem being treated, measuring recovery outcomes a person would notice. Nothing about the animal literature, however extensive, substitutes for that.